

April 8, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Onconova Therapeutics and Trawsfynydd Therapeutics, Inc. Announce
Business Combination to Form Traws Pharma, Inc.**

TOKYO, Japan, April 8, 2024 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") and Trawsfynydd Therapeutics, Inc. ("Trawsfynydd"), a privately-held biotechnology company developing next-generation, antivirals for influenza, COVID and other infectious diseases, announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger") on April 2, 2024 (Eastern Time). Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd's outstanding equity interests. In connection with the transaction and concurrent with the Merger, the combined company has been renamed "Traws Pharma, Inc."

For Onconova's full press release, please visit Onconova's website: <https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-inc-and-trawsfynydd-therapeutics-inc>

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. For more information, please visit <https://www.onconova.com>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, representative: John Houghton). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.